# DDR_bin Retrospective Validation Plan v2.3 (MOAT Edition)

**Date:** January 29, 2025  
**Owner:** GPT (execution) Â· Manager (decisions/claims)  
**Repo of record:** `/Users/fahadkiani/Desktop/development/crispr-assistant-main` (MAIN REPO)  
**Status:** **D1â€“D10 complete through D9 âœ… (remaining: external cohorts)**

---

## ğŸ¯ Core mission (what we are proving)

> **DDR_bin is a treatment-selection biomarker:** it predicts **platinum resistance/response** (mechanistic), even if it does **not** predict survival (PFS/OS) in this cohort.

### Score direction (locked)
- **DDR_bin is a resistance score**: higher = more resistant/refractory.
- Positive class for AUROC benchmarks: **resistant/refractory = 1**, sensitive = 0.

---

## ğŸ§¾ Source-of-truth scripts + artifact directory

### A8 external replication harness (new)

- Script: `oncology-coPilot/oncology-backend-minimal/scripts/validation/validate_ddr_bin_generic_cohort.py`
- Plumber instructions: `.cursor/MOAT/SAE_INTELLIGENCE/PLUMBER_A8_EXTERNAL_REPLICATION.mdc`

### Run Phase 1 validator (A1â€“A3 + plots)

```bash
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/validate_ddr_bin_tcga_ov_survival.py
```

### Run Phase 2/3 analyses (A4 + D5â€“D9 + publication plots)

```bash
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/compute_ddr_bin_competitive_benchmark.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/generate_waterfall_ddr_bin_publication.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/compute_per_diamond_auroc.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/compute_top3_vs_full.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/analyze_ddr_bin_sparsity.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/compare_ddr_bin_aggregation_methods.py
python3 oncology-coPilot/oncology-backend-minimal/scripts/validation/compute_stage_subgroup_auroc.py
```

### Canonical output directory

All artifacts live in:

`oncology-coPilot/oncology-backend-minimal/scripts/validation/out/ddr_bin_tcga_ov/`

---

## âœ… Whatâ€™s delivered (results + files)

### Phase 1 results (A1â€“A3)

- **A1 (PFS/OS)**: no survival signal (expected for response biomarker)
  - PFS: p=0.56
- **A2 (gene-level head-to-head)**: DDR_bin adds value vs gene flag on PFS C-index
  - Î”C-index â‰ˆ **+0.106**
- **A3 (platinum response AUROC)**: **AUROC = 0.698** (predict resistant/refractory)

### Phase 2 competitive benchmark (A4 / Deliverables D1â€“D4)

Computed AUROC (predict resistant/refractory):
- **DDR_bin**: **0.698**
- **Gene DDR (best orientation)**: **0.620**  â†’ **Î” DDR_bin âˆ’ gene DDR = +0.078**
- **TP53 (negative control)**: **0.507**
- **TMB proxy (negative control)**: **0.509**

**Interpretation:** DDR_bin beats the gene-flag baseline and crushes negative controls â†’ mechanism-specific signal.

### D10 publication waterfall
- `waterfall_ddr_bin_publication.png` (300 DPI)

---

## âœ… D5â€“D9 results (interpretability + sparsity + robustness)

### D5: Per-diamond AUROC ranking (9 diamonds)
Top diamonds (AUROC, nonzero rate):
- **feature 9738**: **0.760**, 25/149 nonzero (16.8%)
- **feature 12893**: **0.751**, 35/149 nonzero (23.5%)
- **feature 27607**: **0.747**, 40/149 nonzero (26.8%)

**Artifact:** `per_diamond_auroc.json` + `per_diamond_auroc.csv`

### D6: Top-3 composite vs full DDR_bin
- **Top-3 composite AUROC:** **0.745** (top3 = [9738, 12893, 27607])
- **Full DDR_bin AUROC:** **0.698**
- **Î”(full âˆ’ top3): -0.047**

**Interpretation:** The signal is concentrated in a small subset of diamonds. For *biomarker performance*, top-3 is stronger.

**BUT**: do not change production/validator definition yet without Manager sign-off (definition drift risk).

**Artifact:** `top3_vs_full_comparison.json`

### D7: Sparsity postmortem
- **DDR_bin == 0:** **73/149 (49.0%)**
- **AUROC (all): 0.698**
- **AUROC (nonzero-only): 0.569 (n=76)**

**Interpretation:** â€œNonzero-only AUROCâ€ dropping suggests our **current aggregation** (max_of_max) is not simply â€œmissingness drives signalâ€. Instead, the distribution/label alignment is more complex (and supports trying alternate aggregations).

**Artifacts:**
- `ddr_bin_distribution_analysis.json`
- `ddr_bin_histogram_publication.png` (300 DPI)

### D8: Aggregation method comparison (research)
AUROC (resistant/refractory):
- **mean_of_sum:** **0.707** (best)
- **sum_of_max:** **0.703**
- **top3_mean:** **0.703**
- **max_of_max (current): 0.698**

**Interpretation:** A small improvement exists by switching aggregation (â‰ˆ +0.009). Not a â‰¥0.02 win, but directionally consistent.

**Artifact:** `aggregation_comparison.json`

### D9: Stage robustness (coarse)
- **Stage III:** n=115, **AUROC = 0.707**
- **Stage IV:** n=20, **AUROC = 0.484**
- Unknown stage: 14 rows

**Interpretation:** Stage IV is underpowered (n=20) and does not show signal here; Stage III carries most of the observed discrimination.

**Artifact:** `subgroup_auroc_stage.json`

---

## âœ… Updated decision gates (where we stand)

### Gate 1 (Exploratory / â€œsignal presentâ€) â€” **PASS âœ…**
- PASS if platinum AUROC > 0.65 â†’ **0.698**

### Gate 2 (Publication-ready package) â€” **PASS (core) âœ… / needs external replication ğŸŸ¡**
Core package is now complete:
- âœ… DDR_bin beats gene DDR by â‰¥ 0.05 â†’ **+0.078**
- âœ… DDR_bin beats TP53/TMB by â‰¥ 0.10 â†’ **~+0.19**
- âœ… Publication-quality plots exist (benchmark + waterfall + histogram)
- âœ… Interpretability and robustness diagnostics produced (D5â€“D9)

Remaining for top-tier confidence:
- â³ External cohort replication (ICGC-OV or equivalent)

---

## âœ… Manager decisions (locked)

### 1) Definition lock (production + validator)
- **Decision:** Keep canonical DDR_bin as **`max_of_max`** (current validator definition).
- **Why:** Prevent definition drift and avoid circularity (topâ€‘3 was chosen based on the same cohortâ€™s AUROC ranking).
- **Policy:** Alternative aggregations (**topâ€‘3 composite**, **mean_of_sum**) remain **exploratory diagnostics** until validated on an external cohort or prospectively pre-specified.

### 2) Claim threshold (RUO)
- **Decision:** **AUROC 0.698 is acceptable for RUO positioning**; external-facing copy can say **â€œ~0.70â€**.
- **Allowed RUO claim language:** â€œDDR_bin predicts platinum resistance with AUROC ~0.70, outperforming gene-level DDR status by +8% and demonstrating mechanism-specific discrimination (negative controls ~0.50).â€
- **Restriction:** Do **not** claim â€œclinically validated biomarkerâ€ until prospective replication.

### 3) Stage IV subgroup interpretation
- **Decision:** Treat Stage IV AUROC as **underpowered** (n=20) and report as a limitation, not a failure.

---

## ğŸ“‚ Artifact index (copy/paste)

Directory: `oncology-coPilot/oncology-backend-minimal/scripts/validation/out/ddr_bin_tcga_ov/`

- Phase 1:
  - `report.json`
  - `linked_patients.csv`
  - `roc_platinum_response.png`
  - `waterfall_ddr_bin.png`
  - `km_pfs.png`, `km_os.png`
  - `ddr_bin_hist.png`
- Phase 2/3:
  - `competitive_benchmark.json`
  - `competitive_benchmark.png`
  - `waterfall_ddr_bin_publication.png`
  - `per_diamond_auroc.json`
  - `per_diamond_auroc.csv`
  - `top3_vs_full_comparison.json`
  - `ddr_bin_distribution_analysis.json`
  - `ddr_bin_histogram_publication.png`
  - `aggregation_comparison.json`
  - `subgroup_auroc_stage.json`
